Identification of a new amiodarone metabolite (DDEA) with high myocardial affinity in dogs suggests it may play a role in the drug's pharmacodynamics or side effects.
Answers are grounded in this paper and cite their sources.
May contribute to amiodarone effects in dogs; hypothesis-generating and leaves open human relevance or practice change.
Amiodarone is an antiarrhythmic drug which has received considerable attention in recent years. It has been suggested that the unusual pharmacodynamic characteristics of this drug may be due in part to the influence of active metabolites. Using fast atom bombardment (FAB) mass spectrometry we have identified a new metabolite of amiodarone, the di-N-desethyl analog (DDEA). This metabolite was present in the blood of dogs treated with the parent drug, and showed a greater affinity for myocardium than did the parent drug. The unique features of FAB mass spectrometry over electron impact mass spectrometry was an essential element in facilitating the identification of this new metabolite. Whether or not this metabolite has pharmacologic activity or is responsible for some of the side effects occurring during amiodarone administration is not known.
No takes yet. Share an insight, caveat, or question.
Latini et al. (1984) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: